Growth N. V. Biotech Acquires 75,000 Shares of Radius Health Inc (RDUS) Stock

Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 75,000 shares of the firm’s stock in a transaction on Friday, February 9th. The stock was bought at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the purchase, the insider now owns 5,773,799 shares of the company’s stock, valued at approximately $198,503,209.62. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Radius Health Inc (NASDAQ RDUS) traded up $1.26 during midday trading on Monday, hitting $36.42. 564,597 shares of the stock were exchanged, compared to its average volume of 883,262. The firm has a market capitalization of $1,620.00, a PE ratio of -6.71 and a beta of 1.21. Radius Health Inc has a 52-week low of $24.66 and a 52-week high of $49.16. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.

RDUS has been the subject of several research analyst reports. Jefferies Group decreased their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. Citigroup initiated coverage on shares of Radius Health in a research note on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, BidaskClub downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average target price of $51.78.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. grew its holdings in shares of Radius Health by 19.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 541 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Radius Health by 4.1% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 690 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Radius Health by 14.1% during the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 839 shares during the last quarter. California Public Employees Retirement System grew its holdings in shares of Radius Health by 2.3% during the second quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock valued at $3,238,000 after buying an additional 1,600 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Radius Health by 0.9% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock valued at $5,801,000 after buying an additional 1,674 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Growth N. V. Biotech Acquires 75,000 Shares of Radius Health Inc (RDUS) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/growth-n-v-biotech-acquires-75000-shares-of-radius-health-inc-rdus-stock.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply